Pelthos Therapeutics Inc. (PTHS) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Pelthos Therapeutics Inc. (NYSE: PTHS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $16.54 (+5.08% 1D, market cap $63.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PTHS ranks #717 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PTHS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 76.3%, and ROIC of -35.0%. By comparison, CSBR (Champions Oncology Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, PTHS leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
Per PTHS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001919246), Pelthos Therapeutics Inc. generated $16.8M in revenue, -$43.3M in net income, and -$22.7M in free cash flow against $130.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 26% of 52W Range • RSI-14 at 21.8 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PTHS currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.36) and Max Pain ($17.37) forces dealer call-delta covering toward $39.38.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Pelthos Therapeutics Inc. (PTHS) surged +5.08% to $16.54, trading at 26% of its 52-week range ($9.02 – $37.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary Platforms
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Pelthos Therapeutics Inc. (NYSE:PTHS) ("Pelthos" or the "Company"), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, and Castle Creek
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PTHS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PTHS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Pelthos Therapeutics Inc. (PTHS) ranks #717 by composite RQD confidence (34/100, grade E) and #721 by equity capitalization ($63.3M). Within this direct 5-issuer industry benchmark cohort, PTHS leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with PTHS at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PTHS
ACTIVE
Pelthos Therapeutics Inc. | E | 34/100 | — | 76.3% | -35.0% | +5.08% | $63.3M | Benchmark Subject |
| CSBR Champions Oncology Inc. | E | 22/100 | — | 48.0% | -26.9% | -2.24% | $66.9M | /csbr-vs-pths → |
| CGTX Cognition Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -1.28% | $70.3M | /cgtx-vs-pths → |
| GRML Greenland Mines Ltd. | E | 32/100 | — | — | -35.0% | -5.69% | $70.3M | /grml-vs-pths → |
| CRDF Cardiff Oncology Inc. | D- | 41/100 | — | — | -35.0% | +1.60% | $70.9M | /crdf-vs-pths → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pelthos Therapeutics Inc. (PTHS) reported GAAP revenue of $16.8M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$43.3M, operating cash flow of -$22.6M, and free cash flow of -$22.7M (-291.7% YoY). On the balance sheet, PTHS closed FY2025 with $130.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.8M | -$43.3M | -$22.6M | -$22.7M | $130.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$8.0M | -$5.8M | -$5.8M | $1.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$7.4M | -$981.0K | -$981.0K | — | — |
As of 2026-11-02, Pelthos Therapeutics Inc. (NYSE: PTHS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $16.54 (+5.08% 1D, market cap $63.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PTHS ranks #717 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PTHS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 76.3%, and ROIC of -35.0%. By comparison, CSBR (Champions Oncology Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, PTHS leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).
Per PTHS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001919246), Pelthos Therapeutics Inc. generated $16.8M in revenue, -$43.3M in net income, and -$22.7M in free cash flow against $130.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PTHS last traded at $16.54 (+5.08% on volume of 14,743 shares), positioning the stock -22.57% below its 50-day simple moving average ($21.36) and -31.62% below its 200-day simple moving average ($24.19). Across its 52-week range of $9.02 to $37.50, PTHS sits at the 26.4% percentile with a 14-day RSI of 21.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($14.47 to $18.61).
Why PTHS Stock surged +5.08% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).